BeStock  
Stocks › Biotechnology › RGNX

Regenxbio RGNX

US equityMarket cap rank #3612Biotechnology
$7.16 −$0.02 (-0.28%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.12 -0.56%
Open$7.00
Prev close$7.18
Day range$6.86 – $7.30
Volume1.06M
Market cap$473.44M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership72.9%-6.70 pts vs. prior quarter
Institutions holding210+4 vs. prior quarter
Insider trades (recent)37 buys / 13 sellsNet buying
Short interest15.42% of floatDays to cover 8.3 · as of 30 Oct 2026
Short-sale volume share22.3%5-day average of daily volume

Short-sale volume as % of daily volume

15%23%31%38%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.56M (6 inflow days, 14 outflow days).

Net flow by order size, last 20 sessions

−$1.2MSuper−$401.1KBig+$159.2KMid−$915.9KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 31.8% of shares outstanding.

Largest holders

  • BlackRock11.61%
  • Redmile Group, LLC6.61%
  • Allan Fox4.81%
  • State Street Global Advisors4.77%
  • Vanguard Portfolio Management, LLC4.00%
  • Vanguard Capital Management, LLC3.82%
  • J.P. Morgan Asset Management, Inc.3.23%
  • Morgan Stanley2.74%

By investor type

  • Mutual Fund45.17%
  • Hedge Fund18.22%
  • Individual/Insider6.72%
  • Public Company5.88%
  • Insurance Company1.45%
  • VC/PE Fund1.12%
  • Private Company1.02%
  • Government Pension Fund0.07%

Reported short interest has risen from 12.42% to 15.42% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +1,326,922 5.2%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +1,290,821 4.0%
BlackRock Mutual Fund 2026/Q3 +1,279,154 11.6%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +415,429 3.8%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +341,462 2.4%
TD Asset Management Mutual Fund 2026/Q3 +230,018 0.3%
Franklin Resources Mutual Fund 2026/Q3 +225,571 0.4%
State Street Global Advisors Mutual Fund 2026/Q3 +182,163 4.8%
Acadian Asset Management LLC Mutual Fund 2026/Q3 +138,558 0.2%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +477,567 1.5%
Marshall Wace LLP Hedge Fund 2026/Q3 +1,284,950 1.9%
Citadel Advisors LLC Hedge Fund 2026/Q3 +669,023 1.0%
BlackRock Mutual Fund 2026/Q3 +614,632 9.7%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q3 +426,813 1.1%
Lazard Asset Management LLC Mutual Fund 2026/Q3 +370,375 0.6%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
31 Oct 2026 Stephen Pakola Chief Medical Officer Other Acquisition +34,722 – 187,461
31 Oct 2026 Patrick Christmas Executive VP and Chief Strategy & Legal Officer Other Acquisition +34,722 – 142,764
31 Oct 2026 Mitchell Chan Chief Financial Officer Other Acquisition +24,305 – 127,489
31 Oct 2026 Craig Malzahn Executive VP of Product Development & CTO Other Acquisition +27,777 – 109,737
31 Aug 2026 Mitchell Chan Chief Financial Officer Sale to Issuer -4,902 $9.32 19,632
31 Aug 2026 Craig Malzahn Executive VP of Product Development & CTO Sale to Issuer -234 $9.32 81,960
26 Aug 2026 Gregory Ciongoli Independent Director Open Market Acquisition +102,603 $9.36 102,603
24 Aug 2026 Gregory Ciongoli Independent Director Other Acquisition +15,432 – 15,432
24 Aug 2026 Gregory Ciongoli Independent Director Other Derivative Acquisition +69,609 $8.91 69,609
31 Jul 2026 Stephen Pakola Chief Medical Officer Sale to Issuer -7,468 $9.69 52,802
31 Jul 2026 Patrick Christmas Executive VP and Chief Strategy & Legal Officer Sale to Issuer -4,699 $9.69 97,927
1 Jul 2026 Stephen Pakola Chief Medical Officer Derivative Exercise and Sale -2,161 $13.64 45,673
30 Jun 2026 Curran Simpson Chief Executive Officer Sale to Issuer -6,818 $13.09 54,559
30 Jun 2026 Stephen Pakola Chief Medical Officer Derivative Exercise and Sale -36,725 $12.86 45,673
29 Jun 2026 Curran Simpson Chief Executive Officer Other Acquisition +2,404 $10.18 54,559
28 Jun 2026 Stephen Pakola Chief Medical Officer Automatic Disposition -19,608 $11.04 45,673
28 May 2026 David Stump Independent Director Other Acquisition +9,807 – 9,807
28 May 2026 David Stump Independent Director Other Derivative Acquisition +46,600 $7.01 46,600
28 May 2026 George Migausky Independent Chairperson Other Acquisition +9,807 – 9,807
28 May 2026 George Migausky Independent Chairperson Other Derivative Acquisition +46,600 $7.01 46,600

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 10,179,714 15.4% 8.3
15 Oct 2026 10,043,670 15.2% 6.8
30 Sep 2026 9,608,992 14.6% 6.0
15 Sep 2026 7,927,603 12.0% 7.7
31 Aug 2026 7,497,221 11.4% 4.9
14 Aug 2026 8,197,515 12.4% 7.8

Discussion

No comments yet — be the first to weigh in on RGNX.

Sign in to join the discussion.

Scroll to Top